文章：

局限性弥漫大B细胞淋巴瘤治疗的演变

Evolution of therapy for limited stage diffuse large B-cell lymphoma

原文发布日期：2022-02-24

DOI: 10.1038/s41408-021-00596-z

类型: Review Article

开放获取: 是

英文摘要：

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), with limited-stage DLBCL defined as stage I or II disease. Risk stratification, initial treatment options, and relapse patterns are distinct from advanced-stage DLBCL, but there is limited data on the impact of biologic features on outcome. Patients have excellent outcomes, with ~90% survival at 2 years. Over the past several years, sequential prospective trials and large registry studies have evaluated the optimal number of chemotherapy cycles and implemented PET-adapted approaches to reduce the need for radiotherapy. Special consideration must still be given to cases of bulky disease, extranodal disease, fully resected scenarios, and adverse biologic features such as high-grade B-cell lymphoma with double/triple hit rearrangements. This review presents the evolution of a modern management approach, with a discussion of recent treatment-defining studies.
 

摘要翻译： 

弥漫性大B细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤（NHL），其中局限期DLBCL定义为Ⅰ期或Ⅱ期疾病。其风险分层、初始治疗方案及复发模式与晚期DLBCL存在差异，但生物学特征对预后的影响目前数据有限。此类患者预后良好，2年生存率约达90%。过去数年，一系列前瞻性试验及大型注册研究对最佳化疗周期数进行评估，并采用PET适应策略以减少对放疗的需求。对于大肿块病变、结外病变、已完全切除的病例以及高危生物学特征（如伴有双重/三重打击重排的高级别B细胞淋巴瘤）仍需特别关注。本综述阐述现代治疗策略的演进，并对近期确立治疗标准的研究进行讨论。

原文链接：

Evolution of therapy for limited stage diffuse large B-cell lymphoma